Trial Profile
A Phase III, double blind, randomized, comparative study of the safety and immunogenicity of GSK Biologicals' Varilrix HSA-free varicella vaccine and Varilrix given as a 2 dose course in the second year of life
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs Varicella zoster virus vaccine live (Primary)
- Indications Varicella zoster virus infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline Biologicals; GSK
- 27 Dec 2016 Status changed from recruiting to completed.
- 19 Nov 2016 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 21 Sep 2016 This trial has been completed in the Estonia (30 Jun 2016).